Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Biodesix (BDSX) Shares Outstanding (Diluted Average): 2021-2025

Historic Shares Outstanding (Diluted Average) for Biodesix (BDSX) over the last 5 years, with Sep 2025 value amounting to $7.5 million.

  • Biodesix's Shares Outstanding (Diluted Average) rose 2.53% to $7.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.5 million, marking a year-over-year increase of 2.53%. This contributed to the annual value of $129.7 million for FY2024, which is 57.92% up from last year.
  • Per Biodesix's latest filing, its Shares Outstanding (Diluted Average) stood at $7.5 million for Q3 2025, which was down 94.89% from $146.7 million recorded in Q2 2025.
  • In the past 5 years, Biodesix's Shares Outstanding (Diluted Average) ranged from a high of $146.7 million in Q2 2025 and a low of $2.5 million during Q2 2021.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $82.1 million (2023), whereas its average is $89.1 million.
  • As far as peak fluctuations go, Biodesix's Shares Outstanding (Diluted Average) spiked by 1,457.04% in 2022, and later tumbled by 90.82% in 2024.
  • Over the past 5 years, Biodesix's Shares Outstanding (Diluted Average) (Quarterly) stood at $27.4 million in 2021, then skyrocketed by 53.86% to $42.1 million in 2022, then spiked by 95.03% to $82.1 million in 2023, then soared by 57.92% to $129.7 million in 2024, then grew by 2.53% to $7.5 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $7.5 million for Q3 2025, versus $146.7 million for Q2 2025 and $146.5 million for Q1 2025.